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MAIN TEXT
In this issue of Clinical Cancer Research, Zheng and colleagues found that CSNK2A1, the gene encoding for CK2α, was amplified in 33.7% of 537 glioblastoma (GBM) samples via gene copy number variation analyses of The Cancer Genome Atlas (TCGA) database (1) . GBM is a highly malignant and aggressive disease and is the most common primary intrinsic brain tumor in adults. Patients diagnosed with GBM have a mean survival time of only 15 months (2) . GBM can arise either de novo or from lower-grade astrocytomas. According to differing patterns of patients' gene expression profiles, GBM is classified into four subgroups: proneural, neural, classical, and mesenchymal (2) . The report by Zheng et al. posits that CSNK2A1 amplification is more common in classical GBM (50.7%) than in non-classical GBM (21.3%).
Protein kinase CK2, which has more than 300 substrates, is an important and highly pleiotropic protein kinase, and elevated CK2 kinase activity is frequently observed in many types of human tumors. CK2 is a dual-specificity protein kinase and phosphorylates substrates at serine, threonine, or tyrosine residues with a S/T-X-X-D/E phosphorylation motif (where X is any residue except basic residues). CK2 can function as a tetramer composed of two catalytic subunits⎯CK2α and/or CK2α′ (i.e., αα, αα′, α′α′)⎯and two regulatory subunits⎯CK2β. The two catalytic subunits in the holoenzyme make no contacts with each other (3) . Although CK2 is traditionally regarded as a constitutively active kinase, studies have shown that ERK phosphorylates CK2α at Thr360/Ser362 and activates CK2α in response to growth factor stimuli, including epidermal growth factor (EGF) (4). α-catenin, thereby abrogating the inhibitory effect of α-catenin on β-catenin transactivation induced by EGF (4); CK2 phosphorylates LEF-1 and enhances its binding to nuclear β-catenin in Wnt-signaling cells (5); and CK2 can either increase or decrease cytoplasmic β-catenin stability by phosphorylating β-catenin at different residues or the E2 ubiquitin-conjugating enzyme UBC3B (6, 7). In addition, CK2 can positively regulate PI3K/AKT activity by directly phosphorylating AKT at Ser129 (8) . Moreover, CK2 activates the NF-κB pathway by promoting IκB degradation and phosphorylating p65/RelA at Ser529 to enhance the DNA binding ability of p65/RelA (9). CK2 also phosphorylates Janus kinase (JAK) 1 and 2 and promotes JAK-STAT pathway activation (10) . Furthermore, CK2 inhibition decreases hypoxia-inducible factor-1 (HIF-1) transcription activity without changes in HIF-1α protein level (11) . Given that CK2
regulates multiple signaling pathways involved in tumor cell survival, proliferation, migration, and invasion, downregulation of CK2 by chemical inhibitors or genetic approaches promotes cell apoptosis and inhibits tumor cell migration and tumor growth (12) .
Notably, activation of the Wnt/β-catenin, P13K/AKT, JAK/STAT, and NF-κB pathways has been strongly implicated in GBM development (2) . For instance, EGF receptor, the activation of which upregulates CK2 activity by ERK-dependent phosphorylations is overexpressed or mutated in about 50% of GBMs, which makes it the most frequent genetic alteration associated with GBM (2, 4). In addition, 36% of GBM samples have mutations or homozygous deletions of PTEN and alterations in genes encoding subunits of PI3K (PIK3R1 and PIK3CA) (2). STAT3, which promotes tumor cell survival, proliferation, and angiogenesis, is overexpressed and constitutively activated in GBM. Furthermore, the NF-κB signaling pathway is also highly activated in GBM (2). Zheng et al. revealed that the CK2α gene is amplified in a large percentage of GBMs, and inhibition of CK2 with CX-4945, which is a selective, orally intracranially implanted xenograft models, the authors showed that administration of CX-4945, which reduced STAT-3, NF-κB, and AKT activities in xenograft tumor cells, reduced tumor growth and prolonged the survival of tumor-bearing mice. Importantly, CX-4945 treatment did not affect the mice's body weights, the number of white or red blood cells, or the levels of hemoglobin, indicating minor side effects of CX-4945 on mice.
In summary, CK2, the expression of which is amplified in GBM, regulates several important signaling pathways involved in GBM cell survival, proliferation, and migration and brain tumorigenesis. Treating GBM with CX-4945 or other specific CK2 inhibitors could be an attractive targeted approach and may benefit GBM patients. 
